0YX Stock Overview
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 0YX from our risk checks.
Sysmex Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥14.50 |
| 52 Week High | JP¥22.17 |
| 52 Week Low | JP¥13.67 |
| Beta | 0.52 |
| 1 Month Change | -10.86% |
| 3 Month Change | -9.38% |
| 1 Year Change | -23.68% |
| 3 Year Change | -46.95% |
| 5 Year Change | -13.55% |
| Change since IPO | 29.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0YX | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 5.8% | 2.1% | 0.5% |
| 1Y | -23.7% | -8.4% | 1.3% |
Return vs Industry: 0YX underperformed the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: 0YX underperformed the German Market which returned 1.3% over the past year.
Price Volatility
| 0YX volatility | |
|---|---|
| 0YX Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0YX has not had significant price volatility in the past 3 months.
Volatility Over Time: 0YX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 9,500 | Hisashi Ietsugu | www.sysmex.co.jp |
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Sysmex Corporation Fundamentals Summary
| 0YX fundamental statistics | |
|---|---|
| Market cap | €9.22b |
| Earnings (TTM) | €267.76m |
| Revenue (TTM) | €2.60b |
34.4x
P/E Ratio3.5x
P/S RatioIs 0YX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0YX income statement (TTM) | |
|---|---|
| Revenue | JP¥438.28b |
| Cost of Revenue | JP¥205.29b |
| Gross Profit | JP¥232.99b |
| Other Expenses | JP¥187.93b |
| Earnings | JP¥45.06b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 72.27 |
| Gross Margin | 53.16% |
| Net Profit Margin | 10.28% |
| Debt/Equity Ratio | 6.1% |
How did 0YX perform over the long term?
See historical performance and comparison